| abstract |
The present invention relates to the use of a chemokine receptor binding antibody and / or a chemokine construct for the preparation of a pharmaceutical composition for the elimination of cells that are latently infected with a primate immunodeficiency virus. The invention also relates to the use of a chemokine receptor binding antibody and / or chemokine construct for the manufacture of a medicament for the treatment, prophylaxis or alleviation of inflammatory kidney diseases, inflammatory bowel diseases, multiple sclerosis, skin diseases, diabetes or transplant rejection. The invention further relates to antibody constructs and / or chemokine constructs, more specifically, to constructs wherein said antibody construct contains a binding site for the chemokine 5 receptor, and a CD3 binding site and said chemokine construct include RANTES and a toxin. The present invention further provides said antibody or chemokine construct encoding polynucleotides as well as said nucleic acid molecules comprising vectors and hosts. The present invention further provides compositions comprising said antibody constructs, chemokine constructs, polynucleotides, vectors, and / or host organisms. Said formulation is preferably a pharmaceutical composition. Also disclosed are the use of antibody constructs, chemokine constructs, polynucleotides, hosts, and / or vectors for the preparation of a pharmaceutical composition for treating, preventing and / or ameliorating a single immunological disorder, or eliminating latent infected cells, said cells being the primate immunodeficiency virus, e.g. They are infected with HIV-1. The present invention relates to a method of treating, preventing and / or ameliorating an immunological disorder, or to eliminating cells that are latently infected with a primate immunodeficiency virus. In addition, the invention relates to a kit comprising the compounds of the present invention. HE |